Silence Therapeutics plc (LON:SLN – Get Free Report) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 535 ($6.66) and traded as low as GBX 512 ($6.37). Silence Therapeutics shares last traded at GBX 535 ($6.66), with a volume of 913,528 shares traded.
Silence Therapeutics Trading Down 0.9 %
The company has a current ratio of 4.52, a quick ratio of 4.36 and a debt-to-equity ratio of 0.80. The stock has a market cap of £480.35 million and a P/E ratio of -11.01. The firm’s 50-day simple moving average is GBX 535 and its 200 day simple moving average is GBX 535.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
See Also
- Five stocks we like better than Silence Therapeutics
- Investing in Commodities: What Are They? How to Invest in Them
- Comprehensive Analysis of PayPal Stock
- Why Invest in High-Yield Dividend Stocks?
- Intuitive Surgical Stock Can Trend Much Higher This Year
- What is the Shanghai Stock Exchange Composite Index?
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
